Categories
Uncategorized

Belantamab

 

The FDA has approved belantamab mafodotin-blmf as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody.

 

 

Tradename Blenrep.

 

 

The DREAMM-2 trial, which showed that belantamab mafodotin elicited an overall response rate (ORR) of 31% in patients with relapsed/refractory multiple myeloma who received the treatment at the recommended 2.5 mg/kg dose.

 

 

In patients who received belantamab mafodotin at 3.4 mg/kg, the ORR was 34%.

 

 

Overall, the median duration of response (DOR) was not reached. 

 

 

The median PFS was 2.9 months and 4.9 months in the 2.5-mg/kg and 3.4-mg/kg cohorts, respectively. 

 

 

Overall survival data were immature at the time of the analysis.

 

 

Adverse events included: keratopathy, thrombocytopenia and anemia.

 

 

2.5 mg/kg is the  recommended dose.

 

Leave a Reply

Your email address will not be published. Required fields are marked *